Accumulation of TOX high mobility group box family member 3 promotes the oncogenesis and development of hepatocellular carcinoma through the MAPK signaling pathway

Abstract

Microvascular invasion (MVI) has been widely valued in the field of liver surgery because MVI positivity indicates poor prognosis in hepatocellular carcinoma (HCC) patients. However, the potential molecular mechanism underlying the poor prognosis of MVI-positive HCC patients is unclear. Therefore, this study focused on identifying the key genes leading to poor prognosis in patients with a high degree of malignancy of HCC by examining the molecular signaling pathways in MVI-positive HCC patients. Through RNA sequencing, TOX high mobility group box family member 3 (TOX3) was demonstrated to be significantly highly expressed in MVI-positive HCC tissues, which was associated with poor prognosis. The results of in vivo and in vitro showed that TOX3 can promote the oncogenesis and development of HCC by targeting key molecules of the MAPK and EMT signaling pathways. The IP-MS results indicated that proteasome degradation of TOX3 in HCC cells is potentially mediated by a tripartite motif containing 56 (TRIM56, an E3 ligase) in HCC cells. Inhibiting TRIM56 enhances TOX3 protein levels. Overall, our study identified TOX3 as a key gene in the MAPK and EMT signaling pathways in HCC, and its overexpression confers significant proliferation and invasiveness to tumor cells.

Keywords

growth and metastasis of liver cancer / Hepatocellular carcinoma / insulin-like growth factor binding protein 3 / microvascular invasion / TOX high mobility group box family member 3 / tripartite motif containing 56

References

1	H Sung, J Ferlay, RL Siegel, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
2	A Cucchetti, GL Qiao, M Cescon, et al. Anatomic versus nonanatomic resection in cirrhotic patients with early hepatocellular carcinoma. Surgery. 2014;155(3):512-521.
3	M Rodríguez-Perálvarez, TV Luong, L Andreana, et al. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol. 2013;20(1):325-339.
4	V Mazzaferro, JM Llovet, R Miceli, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1):35-43.
5	M Du, L Chen, J Zhao, et al. Microvascular invasion (MVI) is a poorer prognostic predictor for small hepatocellular carcinoma. BMC Cancer. 2014;14(38).
6	B Wilkinson, JY Chen, P Han, et al. TOX: an HMG box protein implicated in the regulation of thymocyte selection. Nat Immunol. 2002;3(3):272-280.
7	AA Travers. Priming the nucleosome: a role for HMGB proteins? EMBO Rep. 2003;4(2):131-136.
8	P Gaudet, MS Livstone, SE Lewis, et al. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Brief Bioinform. 2011;12(5):449-462.
9	MR Montminy, LM Bilezikjian. Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene. Nature. 1987;328(6126):175-178.
10	DD Ginty, JM Kornhauser, MA Thompson, et al. Regulation of CREB phosphorylation in the suprachiasmatic nucleus by light and a circadian clock. Science. 1993;260(5105):238-241.
11	J Shan, SP Dsouza, S Bakhru, et al. TNRC9 downregulates BRCA1 expression and promotes breast cancer aggressiveness. Cancer Res. 2013;73(9):2840-2849.
12	W Yang, W Wu, H Liang, et al. TOX3 regulates the proliferation and apoptosis of colorectal cancer by downregulating RhoB via the activation of the MAPK pathway. Cell Biol Int. 2022;46(7):1074-1088.
13	Y Wang, Z Wang, C Shao, et al. Melatonin may suppress lung adenocarcinoma progression via regulation of the circular noncoding RNA hsa_circ_0017109/miR-135b-3p/TOX3 axis. J Pineal Res. 2022;73(2):e12813.
14	Y Yang, FF Mao, L Guo, et al. TRIM56 suppresses the malignant development of hepatocellular carcinoma via targeting RBM24 and inactivating the Wnt signaling. Eur Rev Med Pharmacol Sci. 2021;25(2):722-730.
15	H Yan, Z Wang, Y Sun, et al. Cytoplasmic NEAT1 suppresses AML stem cell self-renewal and leukemogenesis through inactivation of Wnt signaling. Adv Sci (Weinh). 2021;8(22):e2100914.
16	K Lu, Y Sui, L Fu. Identification of TRIM56 as a potential biomarker for lung adenocarcinoma. Cancer Manag Res. 2021;13:2201-2213.
17	L Zhao, P Zhang, XJ Su, et al. The ubiquitin ligase TRIM56 inhibits ovarian cancer progression by targeting vimentin. J Cell Physiol. 2018;233(3):2420-2425.
18	S Jogie-Brahim, D Feldman, Y Oh. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev. 2009;30(5):417-437.
19	JL Martin, SM Weenink, RC Baxter. Insulin-like growth factor-binding protein-3 potentiates epidermal growth factor action in MCF-10A mammary epithelial cells. Involvement of p44/42 and p38 mitogen-activated protein kinases. J Biol Chem. 2003;278(5):2969-2976.
20	M Song, Q Pan, J Yang, et al. Galectin-3 favours tumour metastasis via the activation of β-catenin signalling in hepatocellular carcinoma. Br J Cancer. 2020;123(10):1521-1534.
21	RC Baxter. IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer. 2014;14(5):329-341.
22	K Hu, P Lei, Z Yao, et al. Laparoscopic RFA with splenectomy for hepatocellular carcinoma. World J Surg Oncol. 2016;14(1):196.
23	DJ Erstad, KK Tanabe. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol. 2019;26(5):1474-1493.
24	SH Yuan, Z Qiu, A Ghosh. TOX3 regulates calcium-dependent transcription in neurons. Proc Natl Acad Sci U S A. 2009;106(8):2909-2914.
25	WY Kim, MJ Kim, H Moon, et al. Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development. Endocrinology. 2011;152(6):2164-2173.
26	M Takaoka, H Harada, CD Andl, et al. Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer Res. 2004;64(21):7711-7723.
27	JC Chen, ZM Shao, MS Sheikh, et al. Insulin-like growth factor-binding protein enhancement of insulin-like growth factor-I (IGF-I)-mediated DNA synthesis and IGF-I binding in a human breast carcinoma cell line. J Cell Physiol. 1994;158(1):69-78.
28	D Dixit, BC Prager, RC Gimple, et al. The RNA m6A reader YTHDF2 maintains oncogene expression and is a targetable dependency in glioblastoma stem cells. Cancer Discov. 2021;11(2):480-499.
29	Y Liu, H Lv, X Li, et al. Cyclovirobuxine inhibits the progression of clear cell renal cell carcinoma by suppressing the IGFBP3-AKT/STAT3/MAPK-Snail signalling pathway. Int J Biol Sci. 2021;17(13):3522-3537.
30	W Wei, J Jin, S Schlisio, et al. The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell. 2005;8(1):25-33.
31	J Ma, Y Lu, S Zhang, et al. β-Trcp ubiquitin ligase and RSK2 kinase-mediated degradation of FOXN2 promotes tumorigenesis and radioresistance in lung cancer. Cell Death Differ. 2018;25(8):1473-1485.
32	D Zhao, HQ Zheng, Z Zhou, et al. The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation. Cancer Res. 2010;70(11):4728-4738.
33	T Yuan, T Zhou, M Qian, et al. SDHA/B reduction promotes hepatocellular carcinoma by facilitating the deNEDDylation of cullin1 and stabilizing YAP/TAZ. Hepatology. 2023;78(1):103-119.
34	A Lin, CJ Giuliano, A Palladino, et al. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci Transl Med. 2019;11(509).